Emphasize Adherence to Help Boost Hep C Cure Rates
January 2016
More hepatitis C patients will now be treated...due to updated guidelines and a push for fewer payer restrictions.
Most patients will get one or two of the new oral meds, Daklinza (daclatasvir)...Harvoni (ledipasvir/sofosbuvir)...Olysio (simeprevir)...Sovaldi (sofosbuvir)...Technivie (ombitasvir/paritaprevir/ritonavir)...or Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir).
Expect most patients to be treated for 12, 16, or 24 weeks...often based on whether they have cirrhosis or have been treated before.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote